Wow! Two Phase 3 RCTs demonstrate that tozorakimab, an IL33 monoclonal antibody reduces moderate-to-severe COPD exacerbations by 29% to 34%. Kudos to all Oberon, Titania investigators and #ShanaTova to the #CureCOPD community!!!
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Tozorakimab to Prevent COPD Exacerbations | NEJM
Many patients with chronic obstructive pulmonary disease (COPD) have exacerbations
despite receiving standard-of-care inhaled maintenance therapy. Dysregulated interleukin-33
signaling is implicate...
www.nejm.org
September 14, 2026 at 11:16 AM
Wow! Two Phase 3 RCTs demonstrate that tozorakimab, an IL33 monoclonal antibody reduces moderate-to-severe COPD exacerbations by 29% to 34%. Kudos to all Oberon, Titania investigators and #ShanaTova to the #CureCOPD community!!!
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Amazing attendance at the Yale Center for Asthma and Airway Disease 2025: Moving Towards a Unified Approach for the Management of Asthma and COPD
#ScienceMatters #CureCOPD #CureAsthma
#ScienceMatters #CureCOPD #CureAsthma
November 14, 2025 at 5:52 PM
Amazing attendance at the Yale Center for Asthma and Airway Disease 2025: Moving Towards a Unified Approach for the Management of Asthma and COPD
#ScienceMatters #CureCOPD #CureAsthma
#ScienceMatters #CureCOPD #CureAsthma
